Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pedro Martinez-Clark

Interventional Cardiology Miami, FL Medical Doctor

NPI 1205933504 CMS profile 100260

5040 Nw 7Th Street, Suite 750, Miami, FL 33126

Open in the dashboard

General payments

$136,378

597 records reported · program years 2019–2025

Research payments

$20,200

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,588,743 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Pedro Martinez-Clark of Miami, FL is reported in the CMS Open Payments database as having received $136,378 across 597 general payments and $20,200 in research payments paid to them. Separately, studies naming them as principal investigator received $1,588,743 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,699 54
2024 General $8,804 91
2023 General $7,927 78
2022 General $33,734 78
2021 General $39,711 87
2020 General $18,813 76
2020 Research $10,100 7
2019 General $20,690 133
2019 Research $10,100 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pedro Martinez-Clark
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Pedro Martinez-Clark were reported at $6,699. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Pedro Martinez-Clark Interventional Cardiology median Middle half National median
2019 $20,690 $1,097 $329–$3,048 $163
2020 $18,813 $473 $161–$1,480 $114
2021 $39,711 $677 $233–$1,827 $132
2022 $33,734 $978 $333–$2,724 $149
2023 $7,927 $1,136 $382–$2,986 $160
2024 $8,804 $1,181 $395–$3,326 $164
2025 $6,699 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $103,304 17 payments
  2. Medtronic Vascular, Inc. $8,775 67 payments
  3. Abbott Laboratories $7,916 66 payments
  4. Medtronic, Inc. $2,921 61 payments
  5. Alnylam Pharmaceuticals Inc. $1,344 5 payments
  6. Bard Peripheral Vascular, Inc. $1,106 26 payments
  7. Biotronik Inc. $971 8 payments
  8. Boston Scientific Corporation $910 16 payments
  9. AstraZeneca Pharmaceuticals LP $883 56 payments
  10. Janssen Pharmaceuticals, Inc $725 40 payments
  11. Other $7,522 235 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $54,905 6 payments
  2. Long term medical supply or device loan $45,450 5 payments
  3. Food and Beverage $22,766 568 payments
  4. Travel and Lodging $8,257 16 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,000 2 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $57,202 3 payments
  2. VenaCure 1470 Pro Et $19,861 7 payments
  3. Auryon $10,500 1 payment
  4. EVLT $9,600 2 payments
  5. Resolute Stents $7,936 53 payments
  6. Mitra Clip system $5,447 8 payments
  7. VenaCure 1470 Pro Id $4,800 1 payment
  8. XARELTO $725 40 payments
  9. Micra $672 8 payments
  10. Resolute Stents $662 20 payments
  11. Other $15,981 458 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Vifor (International) Ltd. $20,200 14 payments

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

7,173

Median for Interventional Cardiology: 2,236

Drug cost

$1,732,169

Median for Interventional Cardiology: $380,412

Branded share of claims

37.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 409 $427,454
Entresto Sacubitril/Valsartan Brand 321 $369,487
Xarelto Rivaroxaban Brand 250 $261,858
Farxiga Dapagliflozin Propanediol Brand 228 $231,259
Brilinta Ticagrelor Brand 186 $154,116
Jardiance Empagliflozin Brand 70 $82,115
Ozempic Semaglutide Brand 51 $47,808
Repatha Sureclick Evolocumab Brand 34 $31,261
Repatha Syringe Evolocumab Brand 34 $30,340
Verquvo Vericiguat Brand 12 $13,602

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$613,445

Of which drugs: $815

Medicare patients

713

Average age 73

Services billed

4,646

344 women, 369 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 57%
Depression 50%
Ischemic heart disease 44%
Chronic kidney disease 40%
Heart failure 37%
Arthritis 37%
Alzheimer's or dementia 37%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 31 124 $654

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $281
$281 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $114
$114 70 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $113
$113 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $97
$97 250 —
Repatha
  • Amgen Inc. $87
$87 68 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

611 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record